Affordable Access

deepdyve-link
Publisher Website

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease.

Authors
  • Akhtar, Daud H1
  • Iqbal, Umair2
  • Vazquez-Montesino, Luis Miguel3
  • Dennis, Brittany B4, 5
  • Ahmed, Aijaz5
  • 1 Department of Medicine, University of British Columbia Faculty of Medicine, Vancouver BC, Canada. , (Canada)
  • 2 Department of Medicine, Geisinger Commonwealth School of Medicine, Danville, PA, USA.
  • 3 Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • 4 Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton ON, Canada. , (Canada)
  • 5 Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Type
Published Article
Journal
Journal of clinical and translational hepatology
Publication Date
Dec 28, 2019
Volume
7
Issue
4
Pages
362–370
Identifiers
DOI: 10.14218/JCTH.2019.00028
PMID: 31915606
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the developed world, with a global prevalence of around 25%. NAFLD is considered to be the hepatic manifestation of metabolic syndrome and is strongly associated with obesity, insulin resistance and dyslipidemia. Insulin resistance plays a pivotal role in the development of NAFLD-related dyslipidemia, which ultimately increases the risk of premature cardiovascular diseases, a leading cause of morbidity and mortality in patients with NAFLD. Insulin affects hepatic glucose and lipid metabolism by hepatic or extrahepatic pathways. Aside from insulin resistance, several other factors also contribute to the pathogenesis of atherogenic dyslipidemia in patients with NAFLD. These include diet composition, gut microbiota and genetic factors, to name a few. The identification of potentially modifiable risk factors of NAFLD is of importance, so as to target those who may benefit from lifestyle changes and to help develop targeted therapies that decrease the risk of cardiovascular diseases in patients with NAFLD. © 2019 Authors.

Report this publication

Statistics

Seen <100 times